Home Cart Sign in  
Chemical Structure| 516-35-8 Chemical Structure| 516-35-8

Structure of Taurochenodeoxycholic acid
CAS No.: 516-35-8

Chemical Structure| 516-35-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Taurochenodeoxycholic acid-d5 is a natural product.

Synonyms: 12-Deoxycholyltaurine; Taurochenodeoxycholate; Chenyltaurine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Taurochenodeoxycholic acid

CAS No. :516-35-8
Formula : C26H45NO6S
M.W : 499.70
SMILES Code : C[C@@]1([C@@]2([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)[C@](CC2)([H])[C@@]([C@@H](C[C@]3([H])C[C@H](O)CC4)O)([H])[C@]([C@]34C)([H])CC1
Synonyms :
12-Deoxycholyltaurine; Taurochenodeoxycholate; Chenyltaurine
MDL No. :MFCD00232922
InChI Key :BHTRKEVKTKCXOH-BJLOMENOSA-N
Pubchem ID :387316

Safety of Taurochenodeoxycholic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Taurochenodeoxycholic acid

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C. elegans (AT3Q130) 1 μM TUDCA significantly improved the motor defects and extended the lifespan of AT3Q130 nematodes. PMC10904051
THP-1 cells 5–100 μM 24 h To evaluate the inhibitory effects of GCDCA and CDCA on NLRP3 inflammasome activation, results showed that GCDCA was more effective than CDCA in reducing Il1b transcription levels. PMC11662532
Bone-marrow-derived macrophages (BMDMs) 5–100 μM 24 h To evaluate the inhibitory effects of TCDCA and CDCA on NLRP3 inflammasome activation, results showed that TCDCA maintained anti-inflammatory effects at lower concentrations. PMC11662532
Human LX2 cell 6.25–100 μM 48 h TCDCA induced Caspase-11 pyroptosis in human LX2 cells, manifested by increased Caspase-11 and Caspase-3 mRNA expression and balloon-like bubbles under microscopic examination. PMC10067939
Mouse primary HSC 6.25–100 μM 48 h TCDCA induced Caspase-11 pyroptosis in mouse primary HSC, manifested by increased Caspase-11 and Caspase-3 mRNA expression and balloon-like bubbles under microscopic examination. PMC10067939
Mouse primary hepatic cells 6.25–100 μM 24 h TCDCA induced Caspase-11 pyroptosis in mouse primary hepatocytes, manifested by increased Caspase-11 and Caspase-3 mRNA expression, balloon-like bubbles under microscopic examination, and multiple pores formed in the membranes as revealed by TEM. PMC10067939
IEC-6 cells 0.5-1 mM 6 days To investigate the effect of TCDCA on apoptosis resistance in IEC-6 cells, the results showed that TCDCA increased resistance to TNF-α/CHX-induced apoptosis through NF-κB-mediated XIAP expression. PMC1877019
Human adrenocortical H295R cells 100-400 μM 24 or 48 h To investigate the effect of taurochenodeoxycholic acid on cortisol secretion, results showed that TCDCA significantly stimulated cortisol secretion and increased the expression of steroidogenesis-related genes. PMC6899711
Astrocytes 200 μM 24 h To study the effect of TUDCA on LPS and IFN-γ-induced nitrite production in astrocytes, results showed that TUDCA significantly reduced nitrite production. PMC4000131
Microglial cells 200 μM 24 h To study the effect of TUDCA on LPS-induced nitrite production in microglial cells, results showed that TUDCA significantly reduced nitrite production. PMC4000131
Mouse cortical neurons 200 μM 24 h To evaluate the effect of TUDCA on oxidative stress-induced axon degeneration, the results showed that TUDCA significantly increased the number of branch intersections and the length of the axon, indicating that TUDCA alleviated H2O2-induced axon degeneration. PMC8454169

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CMVMJD135 transgenic mice Oral 0.4% (w/w) Continuous administration TUDCA significantly improved the motor behavior and showed neuroprotective effects in CMVMJD135 mice. PMC10904051
Mice Acute pancreatitis model Drinking water 3 mM 4 weeks To evaluate the protective effects of TCDCA on acute pancreatitis, results showed that TCDCA significantly reduced serum amylase and lipase levels and alleviated pancreatic damage. PMC11662532
Mice Thioacetamide (TAA)-induced hepatic fibrosis model Intraperitoneal injection 200 mg/kg Three times per week for 6 weeks TCDCA activated hepatic stellate cells through the MPT-Caspase-11 pyroptosis pathway in the TAA-induced hepatic fibrosis model, ultimately leading to hepatic fibrosis. PMC10067939
Rats Extracorporal bile duct model Intravenous infusion 100 µmol/kg/h Continuous infusion for 54 hours To investigate the effect of taurochenodeoxycholic acid on bile acid synthesis rates, results showed that a high dose of taurochenodeoxycholic acid inhibited taurocholic acid synthesis but had no significant effect on taurochenodeoxycholic and tauromuricholic acid synthesis. PMC303967
Mice FXR and TGR5 knockout mice Diet 1% CDCA diet 5 days To investigate the effect of bile acids on steroidogenesis in mice, results showed that CBDL and CDCA feeding significantly increased corticosterone levels in mice, independent of FXR and TGR5. PMC6899711
C57BL/6 mice Acute neuroinflammation model Intraperitoneal injection 500 mg/kg Every 8 hours for 3 days To study the effect of TUDCA on microglial activation in the LPS-induced acute neuroinflammation model, results showed that TUDCA significantly reduced microglial activation. PMC4000131
Rats Extracorporal bile duct model Intravenous infusion 100 µM/kg 54 hours To study the effect of taurochenodeoxycholic acid on bile acid synthesis, results showed that a high dose of taurochenodeoxycholic acid inhibited taurocholic acid synthesis but had no significant effect on taurochenodeoxycholic acid and tauromuricholic acid synthesis. PMC303967
C57BL/6 mice Spinal cord injury model Oral 200 mg/kg Once daily for 14 days To evaluate the neuroprotective effects of TUDCA in SCI mice, the results showed that TUDCA significantly reduced tissue injury, oxidative stress, inflammatory response, and apoptosis, and promoted axon regeneration and remyelination, improving the recovery of limb function. PMC8454169
Rats High-fat diet-induced obesity model Intra-ileal infusion 100 µM Single dose, 90 minutes To investigate the role of the TCDCA-FXR axis in high-fat diet rats, it was found that TCDCA infusion activated FXR signaling and inhibited ileal nutrient sensing in regulating glucose metabolism. PMC7753965

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

10.01mL

2.00mL

1.00mL

20.01mL

4.00mL

2.00mL

References

 

Historical Records

Categories